|
Market Closed -
Nasdaq
02:30:00 22/01/2026 am IST
|
5-day change
|
1st Jan Change
|
|
44.81 USD
|
+2.35%
|
 |
+1.66%
|
+2.24%
|
|
14/01 |
Truist Securities Adjusts Price Target on Exelixis to $51 From $49, Maintains Buy Rating
|
MT
| |
13/01 |
Exelixis : 260112 Exelixis JP Morgan 2026 Presentation
|
PU
| |
13/01 |
Exelixis, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 05:15 PM
| | |
13/01 |
Tranche Update on Exelixis, Inc.'s Equity Buyback Plan announced on November 4, 2025.
|
CI
| |
13/01 |
Tranche Update on Exelixis, Inc.'s Equity Buyback Plan announced on February 20, 2025.
|
CI
| |
12/01 |
Independence, Under Review
|  | |
12/01 |
Exelixis Provides Fiscal 2026 Revenue Guidance
|
MT
| |
12/01 |
Exelixis says fiscal year 2026 net product revenues guidance of $2.325 billion - $2.425 billion
|
RE
| |
12/01 |
Exelixis : Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026
|
PU
| |
12/01 |
Exelixis, Inc. Announces Preliminary Financial Results for the Year 2025 and Provides Financial Guidance for the Year 2026
|
CI
| |
12/01 |
Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026
|
BU
| |
09/01 |
Sector Update: Health Care Stocks Retreat Late Afternoon
|
MT
| |
09/01 |
Sector Update: Health Care
|
MT
| |
09/01 |
Exelixis Shares Fall After Downgrade From Morgan Stanley
|
MT
| |
08/01 |
Morgan Stanley Downgrades Exelixis to Equalweight, Price Target is $48
|
MT
| |
07/01 |
Enliven Therapeutics, Inc. Announces Changes in Board, Effective January 7, 2026
|
CI
| |
07/01 |
Exelixis, Natera to Collaborate on Phase 3 Colorectal Cancer Trial
|
MT
| |
07/01 |
Exelixis and Natera to collaborate on Stellar-316, a phase 3 pivotal trial of zanzalintinib
|
RE
| |
07/01 |
Exelixis, Inc. and Natera Announce to Collaborate on STELLAR-316, Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer
|
CI
| |
07/01 |
Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer
|
BU
| |
07/01 |
Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026
|
BU
| |
05/01 |
Exelixis Faces Limited High-Impact Catalysts, BofA Says
|
MT
| |
05/01 |
BofA Securities Downgrades Exelixis to Underperform From Neutral, Adjusts Price Target to $41 From $43
|
MT
| |
31/12 |
Exelixis, Inc.'s Equity Buyback announced on February 20, 2025, has closed with 12,271,791 shares, representing 4.5% for $500 million.
|
CI
| |
11/12 |
Exelixis, Inc. - Special Call
| |
No results for this search Select your edition All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
| 
